Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies

被引:2
作者
Wang, Linqin [1 ,2 ,3 ,4 ]
Lv, Yuqi [1 ,2 ,3 ,4 ]
Zhou, Linghui [1 ,2 ,3 ,4 ]
Wu, Shenghao [1 ,5 ]
Zhu, Yuanyuan [1 ,2 ,3 ,4 ]
Fu, Shan [1 ,2 ,3 ,4 ]
Ding, Shuyi [1 ,2 ,3 ,4 ]
Hong, Ruimin [1 ,2 ,3 ,4 ]
Zhang, Mingming [1 ,2 ,3 ,4 ]
Yu, Hanjing [6 ]
Chang, Alex H. [7 ,8 ]
Wei, Guoqing [1 ,2 ,3 ,4 ]
Hu, Yongxian [1 ,2 ,3 ,4 ]
Huang, He [1 ,2 ,3 ,4 ]
机构
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[2] Zhejiang Univ, Liangzhu Lab, Hangzhou, Peoples R China
[3] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
[4] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China
[5] Shanghai Univ, Wenzhou Med Univ, Wenzhou Cent Hosp, Dept Hematol,Dingli Clin Coll,Affiliated Hosp 2, Wenzhou, Peoples R China
[6] Hangzhou Med Coll, Hangzhou, Peoples R China
[7] Shanghai Yake Biotechnol Ltd, Shanghai, Peoples R China
[8] Fudan Univ, Inst Genet, Engn Res Ctr Gene Technol, Sch Life Sci,Minist Educ, Shanghai, Peoples R China
关键词
Cytokine release syndrome; Infection; Fever; Differentiation models; Chimeric antigen receptor; Hematological malignancies;
D O I
10.1186/s40164-024-00495-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although the efficacy of chimeric antigen receptor (CAR)-T cell therapy has been widely demonstrated, its clinical application is hampered by the complexity and fatality of its side effects. Cytokine release syndrome (CRS) is the most common toxicity following CAR-T cell infusion, and its symptoms substantially overlap with those of infection. Whereas, current diagnostic techniques for infections are time-consuming and not highly sensitive. Thus, we are aiming to develop feasible and efficient models to optimize the differential diagnosis in clinical practice. This study included 191 febrile patients from our center, including 85 with CRS-related fever and 106 with infectious fever. By leveraging the serum cytokine profile at the peak of fever, we generated differential models using a classification tree algorithm and a stepwise logistic regression analysis, respectively. The first model utilized three cytokines (IFN-beta, CXCL1, and CXCL10) and demonstrated high sensitivity (90% training, 100% validation) and specificity (98.44% training, 90.48% validation) levels. The five-cytokine model (CXCL10, CCL19, IL-4, VEGF, and CCL20) also showed high sensitivity (91.67% training, 95.65% validation) and specificity (98.44% training, 100% validation). These feasible and accurate differentiation models may prompt early diagnosis of infections during immune therapy, allowing for early and appropriate intervention.
引用
收藏
页数:5
相关论文
共 12 条
[1]   Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children [J].
Diorio, Caroline ;
Shaw, Pamela A. ;
Pequignot, Edward ;
Orlenko, Alena ;
Chen, Fang ;
Aplenc, Richard ;
Barrett, David M. ;
Bassiri, Hamid ;
Behrens, Edward ;
DiNofia, Amanda M. ;
Gonzalez, Vanessa ;
Koterba, Natalka ;
Levine, Bruce L. ;
Maude, Shannon L. ;
Meyer, Nuala J. ;
Moore, Jason H. ;
Paessler, Michele ;
Porter, David L. ;
Bush, Jenny L. ;
Siegel, Don L. ;
Davis, Megan M. ;
Zhang, Donglan ;
June, Carl H. ;
Grupp, Stephan A. ;
Melenhorst, J. Joseph ;
Lacey, Simon F. ;
Weiss, Scott L. ;
Teachey, David T. .
BLOOD ADVANCES, 2020, 4 (20) :5174-5183
[2]   Cytokine Storm [J].
Fajgenbaum, David C. ;
June, Carl H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2255-2273
[3]   Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies [J].
Fishman, Jay A. ;
Hogan, John I. ;
Maus, Marcela V. .
CLINICAL INFECTIOUS DISEASES, 2019, 69 (06) :909-920
[4]   How I treat cytopenias after CAR T-cell therapy [J].
Jain, Tania ;
Olson, Timothy S. ;
Locke, Frederick L. .
BLOOD, 2023, 141 (20) :2460-2469
[5]   Cytokine release syndrome: grading, modeling, and new therapy [J].
Liu, Delong ;
Zhao, Juanjuan .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[6]   Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy [J].
Luo, Hui ;
Wang, Na ;
Huang, Liang ;
Zhou, Xiaoxi ;
Jin, Jin ;
Li, Chunrei ;
Wang, Di ;
Xu, Bin ;
Xu, Jinhuan ;
Jiang, Lijun ;
Wang, Jue ;
Cao, Yang ;
Xiao, Yi ;
Zhang, Qian ;
Mao, Xia ;
Liu, Songya ;
Chen, Liting ;
Xiao, Min ;
Zhou, Jianfeng .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
[7]   Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy [J].
Morris, Emma C. ;
Neelapu, Sattva S. ;
Giavridis, Theodoros ;
Sadelain, Michel .
NATURE REVIEWS IMMUNOLOGY, 2022, 22 (02) :85-96
[8]   The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma [J].
Rejeski, Kai ;
Hansen, Doris K. ;
Bansal, Radhika ;
Sesques, Pierre ;
Ailawadhi, Sikander ;
Logue, Jennifer M. ;
Braeunlein, Eva ;
dos Santos, David M. Cordas M. ;
Freeman, Ciara L. ;
Alsina, Melissa ;
Theurich, Sebastian ;
Wang, Yucai ;
Krackhardt, Angela M. ;
Locke, Frederick L. ;
Bachy, Emmanuel ;
Jain, Michael D. ;
Lin, Yi ;
Subklewe, Marion .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[9]   The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL [J].
Rejeski, Kai ;
Perez, Ariel ;
Iacoboni, Gloria ;
Penack, Olaf ;
Bucklein, Veit ;
Jentzsch, Liv ;
Mougiakakos, Dimitrios ;
Johnson, Grace ;
Arciola, Brian ;
Carpio, Cecilia ;
Blumenberg, Viktoria ;
Hoster, Eva ;
Bullinger, Lars ;
Locke, Frederick L. ;
Von Bergwelt-Baildon, Michael ;
Mackensen, Andreas ;
Bethge, Wolfgang ;
Barba, Pere ;
Jain, Michael D. ;
Subklewe, Marion .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (05)
[10]   Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions [J].
Wat, Jeanette ;
Barmettler, Sara .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (02) :460-466